Cancer Detection on Micro-US (5-fold cross-validation)
78.4AUROCGUIDE-US
Evaluation results
| Method | Links | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| GUIDE-USBase Model=ProstNFound+, Loss=histopathology distillation loss2026.02 | 78.4 | 6.78 | 89.3 | 92.6 | 80.3 | 86 | 64.7 | 64.3 | |
| ProstNFound+2026.02 | 77.9 | 7.32 | 89.4 | 92.1 | 79.1 | 82.5 | 64.5 | 60.2 | |
| ProTeUS2026.02 | 76 | 7.4 | 85.4 | 87.2 | 76.2 | 79.5 | 61.7 | 58.7 | |
| MedSAM2026.02 | 73.5 | 8.1 | 80.8 | 79.9 | 71.6 | 72.2 | 57.1 | 51.4 | |
| SAM2026.02 | 69.2 | 8.4 | 76.2 | 73.1 | 67 | 65.4 | 52.5 | 44.6 |